Publication Name	World Journal of Meta-Analysis
Manuscript ID	61346
Country	India

Received	2020-12-03 08:15
Peer-Review Started	2020-12-03 08:15
To Make the First Decision
Return for Revision	2021-05-06 06:00
Revised	2021-05-20 06:40
Second Decision	2021-06-17 12:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-06-17 12:43
Articles in Press	2021-06-17 12:43
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-06-21 01:00
Typeset the Manuscript	2021-06-27 14:46
Publish the Manuscript Online	2021-07-12 10:23

ISSN	2308-3840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Neurosciences
Manuscript Type	Minireviews
Article Title	Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview
Manuscript Source	Unsolicited Manuscript
All Author List	Bijaylaxmi Behera
Funding Agency and Grant Number
Corresponding Author	Bijaylaxmi Behera, MBBS, MD, Chief Physician, Department of Neonatology, Chaitanya Hospital, Sector 44, Chandigarh 160044, India. jollybubu2008@gmail.com
Key Words	CHERISH; Nusinersen; Spinal muscular atrophy; Survival motor neuron; NURTURE
Core Tip	Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease, with incidence of 1 in 5000 to 1 in 10000 live births. This review provides an elaborative knowledge regarding the current most effective drug for SMA, Nusinersen. A brief discussion on other treatment modalities that are under trials is also provided.
Publish Date	2021-07-12 10:23
Citation	Behera B. Nusinersen, an exon 7 inclusion drug for spinal muscular atrophy: A minireview. World J Meta-Anal 2021; 9(3): 277-285
URL	https://www.wjgnet.com/2308-3840/full/v9/i3/277.htm
DOI	https://dx.doi.org/10.13105/wjma.v9.i3.277

Full Article (PDF)	WJMA-9-277.pdf
Full Article (Word)	WJMA-9-277.docx
Manuscript File	61346-Review-FilipodiaCL.docx
Answering Reviewers	61346-Answering reviewers.pdf
Audio Core Tip	61346-Audio core tip.aac
Conflict-of-Interest Disclosure Form	61346-Conflict-of-interest statement.pdf
Copyright License Agreement	61346-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	61346-Language certificate.pdf
Peer-review Report	61346-Peer-review(s).pdf
Scientific Misconduct Check	61346-Scientific misconduct check.pdf
Scientific Editor Work List	61346-Scientific editor work list.pdf
CrossCheck Report	61346-CrossCheck report.pdf